Yukihiro Takahashi

Randomized controlled trial of magnesium sulfate infusion for severe birth asphyxia

Objective : To determine whether postnatal MgSO4 infusion (250 mg/kg per day) for 3 days is both safe and able to improve outcome in infants with severe birth asphyxia, as had been suggested by a small pilot study.

Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor

Abstract A 17-year-old hemophilia A patient with an intracranial bleeding and a high titre of factor VIII inhibitor was treated with repeated infusion of an activated prothrombin complex concentrate (FEIBA). A good effect was achieved clinically, but laboratory tests on 8th day of the treatment revealed no shortening effect on non-activated partial thromboplastin time and on r-value of thrombelastograph. A prolongation of prothrombin time and thrombin time, a decrease in fibrinogen and antithrombin III, and an increase in serum FDP were also observed. These findings returned to normal after FEIBA was stopped. It was suggested that repeated and massive infusion of FEIBA might cause a decrease in natural inhibitors which lead to DIC.

Intravenous low-dose erythromycin administration for infants with feeding intolerance.

Abstract Background : This study was undertaken to determine the efficacy of low‐dose intravenous erythromycin (EM) administration in infants with feeding intolerance.

Type IIB von Willebrand's Disease: Report on the First Case in Japan

Three members of a family are reported with type IIB von Willebrands disease (vWD), characterized by prolonged bleeding time, increased ristocetin‐induced platelet aggregation, fast anodal migration of factor VIII‐related antigen on crossed immunoelectrophoresis and an absence in plasma and presence in platelets of the larger multimers of factor VIII/von Willebrand factor (FVIII/vWF). Binding ability of the patients FVIII/vWF to washed normal platelets is significantly increased in the presence of low concentrations of ristocetin, whereas binding ability of the patients platelets to normal FVIII/vWF is not increased. These later findings are contrary to those in patients with pseudo‐vWD or platelet type vWD. The administration of DDAVP gives a shortening of bleeding time and an increase in plasma levels of factor VIII‐related activities. In addition, there is a transitory appearance of the larger multimers and a moderate diminution of the platelet count.